Experimental cell therapy takes on stubborn brain autoimmune disorders
NCT ID NCT07021209
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new cell therapy called GT719 in 30 adults with recurrent or hard-to-treat neurological autoimmune diseases. The goal is to see if it is safe and how long the cells last in the body. Researchers will also look for early signs that it might help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GT719 cells (a type of cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat neurological autoimmune diseases.
- What could go wrong
- This is a very early Phase 1 trial with only 30 people, so safety and effectiveness are not yet proven. There may be side effects or the treatment may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.